Pfizer (PFE) Net Income towards Common Stockholders Growth (1y) (2010 - 2025)
Pfizer (PFE) Net Income towards Common Stockholders Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
168.07% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-52.40% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-45.93% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
1,078.32% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
- |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
-9.84% |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
32.85% |
| Date | Value |
|---|
| Jun 29, 2025 |
47.06% |
| Jun 30, 2024 |
950.00% |
| Mar 31, 2024 |
-600.00% |
| Jul 2, 2023 |
-105.88% |
| Apr 2, 2023 |
111.11% |
| Jul 3, 2022 |
114.41% |
| Apr 3, 2022 |
-1,000.00% |
| Oct 3, 2021 |
-102.32% |
| Jul 4, 2021 |
-126.43% |
| Apr 4, 2021 |
-99.89% |
| Sep 27, 2020 |
13,900.00% |
| Dec 31, 2019 |
-27.38% |
| Sep 29, 2019 |
-63.64% |
| Dec 31, 2018 |
365,800.00% |
| Dec 31, 2017 |
-87.50% |
| Jul 2, 2017 |
100.00% |
| Dec 31, 2016 |
180.00% |
| Jul 3, 2016 |
0.00% |
| Dec 31, 2015 |
-33.33% |
| Sep 27, 2015 |
366.67% |
